A Dose-ranging, Safety, and Efficacy Trial with Zafirlukast (ACCOLATE) in the Treatment of Pediatric Subjects with Mild-to-moderate Asthma; up to a 52-week Open-label Safety Extension (9188IL/0139). Report for the Open-label Extension only.

Study identifier:9188IL/0139

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Dose-ranging, Safety, and Efficacy Trial with Zafirlukast (ACCOLATE) in the Treatment of Pediatric Subjects with Mild-to-moderate Asthma; up to a 52-week Open-label Safety Extension (9188IL/0139). Report for the Open-label Extension only.

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Feb 1997
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria